Aspen Aerogels price target lowered to $3 from $6 at Roth Capital

Roth Capital analyst Chip Moore lowered the firm’s price target on Aspen Aerogels (ASPN) to $3 from $6 and keeps a Buy rating on the shares after its Q4 earnings miss. While near-term visibility stays challenging given policy dynamics and a demand reset for key customer GM, the firm sees underlying platform value and an attractive longer-term opportunity, the analyst tells investors in a research note.